maridebart cafraglutide
Sponsor Amgen INC · listed as AMGN
maridebart cafraglutide is a drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 6 forward catalysts for it — the nearest is a readout expected Jan 21, 2027 (day precision, medium confidence), tied to trial NCT06858839. That trial is in Phase 3 and currently active not recruiting, studying Obesity. It appears across 10 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for maridebart cafraglutide
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-01-21 | READOUT | medium | NCT06858839 |
| 2027-04-27 | READOUT | medium | NCT06987695 |
| 2027-08-30 | READOUT | medium | NCT07226765 |
| 2027-09-03 | READOUT | medium | NCT07225686 |
| 2027-12-26 | READOUT | medium | NCT07684144 |
| 2028-01-03 | READOUT | medium | NCT07575399 |
Trials for maridebart cafraglutide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06858839 catalyst | Phase 3 | Active, not recruiting | 2027-01-21 | Experimental | Amgen | Obesity |
| NCT06858878 | Phase 3 | Active, not recruiting | 2027-01-21 | Experimental | Amgen | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight |
| NCT06987695 catalyst | Phase 3 | Active, not recruiting | 2027-04-27 | Experimental | Amgen | Obesity Disease |
| NCT07226765 catalyst | Phase 3 | Active, not recruiting | 2027-08-30 | Experimental | Amgen | Obstructive Sleep Apnea |
| NCT07225686 catalyst | Phase 3 | Active, not recruiting | 2027-09-03 | Experimental | Amgen | Obesity; Obstructive Sleep Apnea |
| NCT07684144 catalyst | Phase 3 | Recruiting | 2027-12-26 | Experimental | Amgen | Obesity; Overweight; Diabetes Mellitus, Type 2 |
| NCT07684235 | Phase 3 | Recruiting | 2027-12-26 | Experimental | Amgen | Obesity; Overweight |
| NCT07575399 catalyst | Phase 3 | Recruiting | 2028-01-03 | Experimental | Amgen | Obesity or Overweight |
| NCT07037433 | Phase 3 | Recruiting | 2028-06-30 | Experimental | Amgen | Atherosclerotic Cardiovascular Disease; Overweight; Obesity |
| NCT07037459 | Phase 3 | Recruiting | 2028-06-30 | Experimental | Amgen | Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection… |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AMGN catalysts